These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21182343)

  • 21. Costing of scaling up HIV/AIDS treatment in Mexico.
    Bautista-Arredondo S; Dmytraczenko T; Kombe G; Bertozzi SM
    Salud Publica Mex; 2008; 50 Suppl 4():S437-44. PubMed ID: 19082254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.
    Hubben GA; Bishai D; Pechlivanoglou P; Cattelan AM; Grisetti R; Facchin C; Compostella FA; Bos JM; Postma MJ; Tramarin A
    AIDS Care; 2008 Apr; 20(4):449-55. PubMed ID: 18449822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative analysis of outpatient costs in HIV treatment programs.
    Sarti FM; Nishijima M; Campino AC; Cyrillo DC
    Rev Assoc Med Bras (1992); 2012; 58(5):561-7. PubMed ID: 23090227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989.
    Beck EJ; Kennelly J; McKevitt C; Whitaker L; Wadsworth J; Miller DL; Easmon C; Pinching AJ; Harris JR
    AIDS; 1994 Mar; 8(3):367-77. PubMed ID: 8031516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand.
    Kitajima T; Kobayashi Y; Chaipah W; Sato H; Chadbunchachai W; Thuennadee R
    AIDS; 2003 Nov; 17(16):2375-81. PubMed ID: 14571190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
    Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
    Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cost of Illness of HIV Patients under Anteretroviral Therapy in Germany - Results of the 48-Week Interim Analysis of the Prospective Multicentre Observational Study 'CORSAR'].
    Kuhlmann A; Mittendorf T; Hower M; Heiken H; Gerschmann S; Klauke S; Lutz T; Bogner J; Degen O; van Lunzen J; Bachmann C; Stellbrink HJ; Schmidt W; Leistner I; Mahlich J; Ranneberg B; Stoll M
    Gesundheitswesen; 2015 Jun; 77(6):e133-42. PubMed ID: 25247761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization.
    Sansom SL; Anthony MN; Garland WH; Squires KE; Witt MD; Kovacs Andrea A; Larsen RA; Valencia R; Pals SL; Hader S; Weidle PJ; Wohl AR
    AIDS Patient Care STDS; 2008 Feb; 22(2):131-8. PubMed ID: 18260804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.
    Yazdanpanah Y; Goldie SJ; Losina E; Weinstein MC; Lebrun T; Paltiel AD; Seage GR; Leblanc G; Ajana F; Kimmel AD; Zhang H; Salamon R; Mouton Y; Freedberg KA
    Antivir Ther; 2002 Dec; 7(4):257-66. PubMed ID: 12553480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
    Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients].
    Llibre-Codina JM; Casado-Gómez MA; Sánchez-de la Rosa R; Pérez-Elías MJ; Santos-González J; Miralles-Alvarez C; Martínez-Chamorro E; Domingo-Pedrol P; Alvarez-García ML; Moreno-Guillén S
    Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):98-107. PubMed ID: 17288907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Study on the utilization of health services and costs of hospital-based medical care for 29 patients with HIV/AIDS in China].
    Yang HM; Li J; Wu ZY; Xu LZ; Wang KA
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 May; 24(5):393-6. PubMed ID: 12820935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs of care provided in a university hospital for children exposed to or infected with the HIV/AIDS.
    Marques HH; Couttolenc BF; Latorre Mdo R; Aquino MZ; Aveiro MI; Pluciennik AM
    Cad Saude Publica; 2007; 23 Suppl 3():S402-13. PubMed ID: 17992346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between quality-of-care indicators for HIV infection and healthcare resource utilization and costs.
    Nduaguba SO; Barner JC; Ford KH; Lawson KA; Barnes JN; Wilson JP
    AIDS; 2020 Feb; 34(2):291-300. PubMed ID: 31714351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost of HIV disease in Northern Italy: the payer's perspective.
    Rizzardini G; Restelli U; Bonfanti P; Porazzi E; Ricci E; Casartelli L; Foglia E; Carenzi L; Citterio P; Orlando G; Maselli C; Croce D
    J Acquir Immune Defic Syndr; 2011 Jul; 57(3):211-7. PubMed ID: 21546850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Economic burden and clinical course of HIV infection and AIDS today: how the variation of natural history, available treatments, and strictly related costs play a role in needs of health care].
    Manfredi R; Calza L; Gramegna A; Bocchi F; Fiacchi P; Corsini D; Chiodo F
    Recenti Prog Med; 2001 Nov; 92(11):648-54. PubMed ID: 11765655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection: a substudy of the ANRS 106 Window Trial.
    Charreau I; Jeanblanc G; Tangre P; Boyer L; Saouzanet M; Marchou B; Molina JM; Aboulker JP; Durand-Zaleski I;
    J Acquir Immune Defic Syndr; 2008 Dec; 49(4):416-21. PubMed ID: 18931625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Geographic variation in the costs of medical care for people living with HIV in British Columbia, Canada.
    Enns B; Min JE; Panagiotoglou D; Montaner JSG; Nosyk B;
    BMC Health Serv Res; 2019 Sep; 19(1):626. PubMed ID: 31481056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.